Provided are compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.

The invention provides reagents and methods for enzyme replacement therapy using chemically modified species of human cystathionine ?-synthase (CBS) to treat homocystinuria and other related diseases and disorders.

The invention provides reagents and methods for enzyme replacement therapy using chemically modified species of human cystathionine ?-synthase (CBS) to treat homocystinuria and other related diseases and disorders.

Provided are compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.

Human cystathionine -synthase variants are disclosed, as well as a method to produce recombinant human cystathionine -synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologues are described. In addition, a method to express and purify recombinant human cystathionine -synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described.

Provided herein are improved compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.

Provided herein are improved compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.

Provided herein are improved compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.

The present disclosure relates to a microorganism producing O-acetylhomoserine with high efficiency and a method for producing O-acetylhomoserine and L-methionine using the microorganism. The present disclosure provides a microorganism producing O-acetylhomoserine having an enhanced activity of a protein which is predicted to export O-acetylhomoserine, and a method for producing O-acetylhomoserine and L-methionine using the microorganism.

Human cystathionine -synthase variants are disclosed, as well as a method to produce recombinant human cystathionine -synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologues are described. In addition, a method to express and purify recombinant human cystathionine -synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described.